News Conference News ACC 2024 PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE L.A. McKeown April 08, 2024
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Daily News High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention Michael O'Riordan February 29, 2024
News Daily News Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds L.A. McKeown February 23, 2024
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News Top General Cardiology and CVD Prevention News of 2023 Yael L. Maxwell January 03, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Conference News AHA 2023 New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference? Shelley Wood November 13, 2023
News Conference News AHA 2023 Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH Caitlin E. Cox November 12, 2023
News Daily News Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals Yael L. Maxwell October 19, 2023
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Daily News Statin Therapy Still Lacking for Many US Patients With ASCVD L.A. McKeown August 07, 2023
News Daily News Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA L.A. McKeown July 11, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Daily News Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2 Michael O'Riordan June 14, 2023
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023